AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38861967 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38862073 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mononuclear cells
Number of subjects: 110
Study 38862073 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 110
Study 38862134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 647
Study 38862134 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 647
Study 38862179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily)
Number of subjects: 500
Study 38862179 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor monotherapy (90 mg twice daily)
Number of subjects: 500
Study 38862179 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy (100 mg once daily)
Number of subjects: 500
Study 38862183 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS burden of ≥3
Number of subjects: 111
Study 38862183 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved NIS burden
Number of subjects: 111
Study 38862183 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS management
Number of subjects: 111
Study 38862220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleic acid amplification test (NAAT)
Number of subjects: 220
Study 38862220 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (syndromic management)
Number of subjects: 220
Study 38862228 — intervention group
Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 1750
Study 38862228 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Disability Assessment Schedule (WHODAS) 2.0
Number of subjects: 1750
Study 38862228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality follow-up
Number of subjects: 1750
Study 38862251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab 240 mg every 3 weeks (three cycles) combined with axitinib 5 mg twice daily for up to 12 weeks.
Number of subjects: 20
Study 38862251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab combined with axitinib.
Number of subjects: 20
Study 38862308 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus peer-led vaccine counseling
Number of subjects: 144
Study 38862308 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 144
Study 38862303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 0
Study 38862381 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 96
Study 38862381 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 96
Study 38862718 — intervention group
Group type: EXPERIMENTAL
Intervention: Linerixibat for 12 weeks
Number of subjects: 147
Study 38862718 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 147
Study 38862742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib for 1 year
Number of subjects: 69
Study 38862742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib for 3 years
Number of subjects: 69
Study 38862815 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered mindfulness interventions
Number of subjects: 0
Study 38862815 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 38862831 — intervention group
Group type: EXPERIMENTAL
Intervention: Current trial (ongoing randomized trial post-pandemic)
Number of subjects: 0
Study 38862831 — intervention group
Group type: COMPARATOR
Intervention: Prior studies (two randomized trials conducted before the pandemic)
Number of subjects: 0
Study 38862899 — intervention group
Group type: EXPERIMENTAL
Intervention: CO-DEPRESCRIBE training program
Number of subjects: 167
Study 38862899 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 167
Study 38862908 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day orally for 14 days on and 7 days off) and nivolumab (360 mg every 3 weeks)
Number of subjects: 21
Study 38862908 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib and nivolumab
Number of subjects: 21
Study 38862912 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES), 30-min quadriceps NMES, 3 days per week for 12 weeks
Number of subjects: 15
Study 38862912 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 15
Study 38863022 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessments including NPC1 severity rating scale, videofluoroscopic swallowing studies, and CSF collection.
Number of subjects: 14
Study 38863022 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk analysis of aspiration
Number of subjects: 14
Study 38863022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modifications recommended
Number of subjects: 14
Study 38863022 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing outcomes analysis
Number of subjects: 14
Study 38863026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-oxygen gas mixture inhalation (8 hours per day, 3 L/min, hydrogen concentration of 67%, oxygen concentration of 33%)
Number of subjects: 206
Study 38863026 — intervention group
Group type: COMPARATOR
Intervention: Oxygen inhalation (8 hours per day, 3 L/min, oxygen concentration of 33%)
Number of subjects: 206
Study 38863155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidanacogene elaparvovec (gene therapy)
Number of subjects: 0
Study 38863155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous FIX replacement products
Number of subjects: 0
Study 38863155 — intervention group
Group type: COMPARATOR
Intervention: Wild-type FIX control
Number of subjects: 0
Study 38863591 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula with extra virgin olive oil (administered 5 days before surgery)
Number of subjects: 119
Study 38863591 — intervention group
Group type: COMPARATOR
Intervention: Standard isoprotein and isoenergetic formula (control group)
Number of subjects: 119
Study 38863605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Horsemanship (AH) lessons for 8 weeks
Number of subjects: 9
Study 38863605 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 9
Study 38863672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive inpatient trauma treatment program with prolonged exposure (PE), eye movement desensitization and reprocessing (EMDR), and therapist rotation (TR)
Number of subjects: 6
Study 38863672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive inpatient trauma treatment program
Number of subjects: 6
Study 38863717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir + optimized background therapy
Number of subjects: 371
Study 38864156 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised TKA
Number of subjects: 28
Study 38864156 — intervention group
Group type: COMPARATOR
Intervention: OTS TKA
Number of subjects: 28
Study 38864165 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised TKA
Number of subjects: 385
Study 38864165 — intervention group
Group type: COMPARATOR
Intervention: OTS TKA
Number of subjects: 385
Study 38864155 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Number of subjects: 7031
Study 38864155 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Number of subjects: 7031
Study 38864155 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of β-lactam antibiotics
Number of subjects: 7031
Study 38864155 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of β-lactam antibiotics
Number of subjects: 7031
Study 38864228 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular VP replacement (every 3 months)
Number of subjects: 52
Study 38864228 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular VP replacement (when complications occur)
Number of subjects: 52
Study 38864228 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 patients)
Number of subjects: 52
Study 38864363 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (steroid)
Number of subjects: 686
Study 38864363 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine, mycophenolate mofetil, mizoribine, or cyclophosphamide (alone or in combination with steroid therapy)
Number of subjects: 686
Study 38864363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil, vitamin E, and tonsillectomy
Number of subjects: 686
Study 38864363 — intervention group
Group type: EXPERIMENTAL
Intervention: Other immunosuppressive therapies
Number of subjects: 686
Study 38864363 — intervention group
Group type: COMPARATOR
Intervention: Steroids, other immunosuppressive therapies, or tonsillectomy (when added to optimal supportive care)
Number of subjects: 686
Study 38864441 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful MitraClip placement
Number of subjects: 30
Study 38864472 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 163
Study 38864472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 38864524 — intervention group
Group type: EXPERIMENTAL
Intervention: HIL-214 (formerly TAK-214) vaccine
Number of subjects: 24
Study 38864538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 593
Study 38864538 — intervention group
Group type: COMPARATOR
Intervention: Thermal Ablation
Number of subjects: 593
Study 38864600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg b.i.d. plus 1.2 mg midazolam (MDZ) on Days 11 and 14
Number of subjects: 15
Study 38864600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg b.i.d. alone on Days 8-10
Number of subjects: 15
Study 38864600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 200 mg b.i.d. alone on Days 5-7
Number of subjects: 15
Study 38864600 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MDZ) 1.2 mg alone on Day 1
Number of subjects: 15
Study 38864600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg b.i.d. on Days 11 and 14
Number of subjects: 15
Study 38864802 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-T cells (75,000 or 150,000 IFN-γ+CD3+ cells/m)
Number of subjects: 13
Study 38864835 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ctDNA not detected
Number of subjects: 143
Study 38864835 — intervention group
Group type: COMPARATOR
Intervention: Postoperative ctDNA detected
Number of subjects: 143
Study 38864835 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark negative predictive value (NPV)
Number of subjects: 143
Study 38864835 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal sensitivity
Number of subjects: 143
Study 38864835 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal specificity
Number of subjects: 143
Study 38864835 — intervention group
Group type: EXPERIMENTAL
Intervention: Median lead time from ctDNA detection to radiological recurrence
Number of subjects: 143
Study 38864969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 20% (1.5 ml/kg) administered 3 min before aortic cross unclamping
Number of subjects: 26
Study 38864969 — intervention group
Group type: COMPARATOR
Intervention: Ringer's Lactate (control group) administered 3 min before aortic cross unclamping
Number of subjects: 26
Study 38864969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Number of subjects: 26
Study 38864969 — intervention group
Group type: COMPARATOR
Intervention: Ringer's Lactate (control group)
Number of subjects: 26
Study 38865006 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-pronged intervention including access to an online equity dashboard and equity huddles with population health coordinators (PHCs).
Number of subjects: 10865
Study 38865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA)
Number of subjects: 33
Study 38865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Troriluzole (from phase 3 trial NCT03701399)
Number of subjects: 33
Study 38865064 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-vitamin E group (n = 40) received oral zinc (120 mg) and vitamin E (1200 IU) before surgery, followed by 30 mg of zinc and 200 IU of vitamin E daily until 21 days after surgery.
Number of subjects: 78
Study 38865064 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 38) received placebo.
Number of subjects: 78
Study 38865064 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-vitamin E group (n = 40)
Number of subjects: 78
Study 38865064 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 38)
Number of subjects: 78
Study 38865084 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal immune responses to CMV, including anti-pentamer immunoglobulin G antibody concentration and viral load in saliva.
Number of subjects: 0
Study 38865084 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral loads in urine and saliva samples from mothers of infants with cCMV.
Number of subjects: 0
Study 38865129 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri high dose (5×10^9 CFU)
Number of subjects: 239
Study 38865129 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri low dose (5×10^8 CFU)
Number of subjects: 239
Study 38865129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 38865142 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromuscular Sugarbaker mesh placement
Number of subjects: 150
Study 38865142 — intervention group
Group type: COMPARATOR
Intervention: Keyhole synthetic mesh placement
Number of subjects: 150
Study 38865146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg) subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311
Study 38865146 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311
Study 38865147 — intervention group
Group type: EXPERIMENTAL
Intervention: Early in-bed Cycling + Usual physiotherapy (n=178)
Number of subjects: 360
Study 38865147 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy alone (n=182)
Number of subjects: 360
Study 38865168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (2 g per kilogram of ideal body weight per day)
Number of subjects: 3511
Study 38865168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Ringer's solution)
Number of subjects: 3511
Study 38865168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids
Number of subjects: 3511
Study 38865168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3511
Study 38865173 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth tool (eDOL)
Number of subjects: 1427
Study 38865181 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered weight loss programs for cancer survivors
Number of subjects: 340
Study 38865190 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat swab including specimens from the palatine tonsils
Number of subjects: 2315
Study 38865190 — intervention group
Group type: COMPARATOR
Intervention: Throat swab from the posterior oropharyngeal wall only
Number of subjects: 2315
Study 38865296 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent to midwifery practices and interventions
Number of subjects: 2849
Study 38865296 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practices and interventions (e.g., warm compresses, manual perineal protection, vaginal examinations, perineal massage, levator pressure, intermittent catheterization, fundal pressure, episiotomy)
Number of subjects: 2849
Study 38865672 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 28
Study 38865671 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing-based molecular assay using urine samples
Number of subjects: 64
Study 38865678 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab
Number of subjects: 0
Study 38865678 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 38865678 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Atezolizumab)
Number of subjects: 0
Study 38865703 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated telemedicine for HCV management
Number of subjects: 45
Study 38865704 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapist-guided mindfulness-based cognitive behavioral therapy (CBT-M)
Number of subjects: 28
Study 38865704 — intervention group
Group type: COMPARATOR
Intervention: Web-based therapist-guided cognitive behavioral therapy (CBT)
Number of subjects: 28
Study 38866072 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnelide 1.5 mg as monotherapy (Regimen A)
Number of subjects: 11
Study 38866072 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnelide 1.25 mg once daily for 21 days Q4 weeks as monotherapy (MTD)
Number of subjects: 11
Study 38866072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Minnelide plus paclitaxel (Regimen B & C)
Number of subjects: 11
Study 38866072 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnelide (Regimen A)
Number of subjects: 11
Study 38866095 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) before CPB
Number of subjects: 0
Study 38866095 — intervention group
Group type: COMPARATOR
Intervention: Best available treatment without ANH
Number of subjects: 0
Study 38866096 — intervention group
Group type: EXPERIMENTAL
Intervention: HARMONY 1: culturally-tailored exercise and nutrition education
Number of subjects: 200
Study 38866096 — intervention group
Group type: EXPERIMENTAL
Intervention: HARMONY 2: mindfulness-based stress reduction, exercise, and nutrition education
Number of subjects: 200
Study 38866139 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCI
Number of subjects: 60
Study 38866139 — intervention group
Group type: COMPARATOR
Intervention: Leadership training webinar
Number of subjects: 60
Study 38866180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel
Number of subjects: 494
Study 38866180 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel
Number of subjects: 494
Study 38866366 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared spectroscopy
Number of subjects: 37
Study 38866366 — intervention group
Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Number of subjects: 37
Study 38866366 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic circular dichroism
Number of subjects: 37
Study 38866366 — intervention group
Group type: EXPERIMENTAL
Intervention: Raman optical activity
Number of subjects: 37
Study 38866366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined classification model based on all spectroscopic methods
Number of subjects: 37
Study 38866559 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block (20 mL of 0.3% ropivacaine)
Number of subjects: 80
Study 38866559 — intervention group
Group type: COMPARATOR
Intervention: SIFICB (30 mL of 0.3% ropivacaine)
Number of subjects: 80
Study 38866567 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) in addition to usual care (UC)
Number of subjects: 92
Study 38866567 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study 38866575 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 120
Study 38866575 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based individual therapy for insomnia (iCBT-I) + TAU
Number of subjects: 120
Study 38866575 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy for insomnia (GCBT-I) + TAU
Number of subjects: 120
Study 38866577 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of hepatic artery complications (HAC) after liver transplantation
Number of subjects: 0
Study 38866822 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cell therapy (as referenced in the BNT-211-01 trial, NCT04503278)
Number of subjects: 6
Study 38866860 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year structured weight loss intervention
Number of subjects: 246
Study 38866860 — intervention group
Group type: COMPARATOR
Intervention: Baseline data
Number of subjects: 246
Study 38866860 — intervention group
Group type: COMPARATOR
Intervention: Changes from baseline to follow-up
Number of subjects: 246
Study 38866963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 147
Study 38866963 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological assessment
Number of subjects: 147
Study 38867006 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90-anti-CD66 antibody
Number of subjects: 0
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC flow 30 l/min, open mouth
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC flow 30 l/min, closed mouth
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC flow 70 l/min, open mouth
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC flow 70 l/min, closed mouth
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between pressure difference and respiratory effort
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 30 l/min - closed mouth
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 30 l/min - open mouth
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 70 l/min - closed mouth
Number of subjects: 25
Study 38867018 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 70 l/min - open mouth
Number of subjects: 25